麻豆传媒

Pfizer Global Medical Grants (GMG) supports the global healthcare community鈥檚 independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer鈥檚 medical and/or scientific strategies.

Pfizer鈥檚 GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Date RFP Issued: April 27, 2023
Geographic Scope: Canada
Clinical Area: Transthyretin Amyloid Cardiomyopathy
Link to full RFP:
Application Due Date: June 19, 2023

Refer to complete details in the .聽If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).

Specific Area of Interest:聽Pfizer is interested in supporting proposals that advance our understanding of the basic science and early diagnosis and treatment of ATTR cardiac amyloidosis through research. See Area of Interest section of RFP for further details.

Questions regarding internal procedure may be directed to聽ird@dal.ca.聽For additional resources,聽click here for guidance聽on internal deadlines and submission processes.